Efficacy and safety of androgen deprivation therapy after switching from monthly leuprolide to monthly degarelix in patients with prostate cancer.

de la Rosette J, Davis R 3rd, Frankel D, Kold Olesen T

International journal of clinical practice22 Feb 2011Cited by 16 (Europe PMC)

PMID21342376DOI10.1111/j.1742-1241.2011.02637.xPepBankPUB-21342376

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanNon-randomized trialEfficacy outcome
In prostate cancer patients switching to degarelix, testosterone, LH and PSA levels remained sustained in both dose groups.
In plain wordsIn prostate cancer patients switching to degarelix, testosterone, LH and PSA levels remained sustained in both dose groups.
Peptide
Degarelix
Outcome
No significant changeMaintenance of testosterone, LH and PSA
Study
n = 134
Comparator
Before switch from leuprolide
Outcome group
Biochemical Disease Control · Cancer
Studied dose
240 mg initial, then 80 or 160 mg monthly · 3 monthsAs given in this study (human).
Source sentences
Summary
Serum testosterone, LH, and PSA levels were all sustained in both treatment arms during the observation period.
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were 134 patients with histologically confirmed PCa who had completed 1 year of treatment with leuprolide 7.5 mg monthly before being switched to degarelix.
Summary · context
These patients were re-randomised for the extension trial to receive a starting dose of 240 mg degarelix followed by monthly maintenance doses of either 80 (n = 69) or 160 mg (n = 65).
Report a problemFND-2134237601
02HumanNon-randomized trialEfficacy outcome
In prostate cancer patients, switching from leuprolide to degarelix further reduced FSH by 30%.
In plain wordsIn prostate cancer patients, switching from leuprolide to degarelix further reduced FSH by 30%.
Peptide
Degarelix
Outcome
DecreaseFSH reduction after switch
Study
n = 134
Comparator
Before switch from leuprolide
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
240 mg initial, then 80 or 160 mg monthly · 3 monthsAs given in this study (human).
Measurements
FSH reduction
30%
after switch to degarelix
Source sentences
Summary
Interestingly, FSH levels were further decreased by 30% following the switch to degarelix.
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were 134 patients with histologically confirmed PCa who had completed 1 year of treatment with leuprolide 7.5 mg monthly before being switched to degarelix.
Summary · context
These patients were re-randomised for the extension trial to receive a starting dose of 240 mg degarelix followed by monthly maintenance doses of either 80 (n = 69) or 160 mg (n = 65).
Report a problemFND-2134237602
03HumanNon-randomized trialSafety outcome
In prostate cancer patients switching to degarelix, adverse event prevalence and pattern were comparable to prior leuprolide treatment, except injection site reactions.
In plain wordsIn prostate cancer patients, adverse events were comparable after switching to degarelix from leuprolide, except injection site reactions.
Peptide
Degarelix
Outcome
No significant changeOverall adverse event prevalence and pattern
Study
n = 134
Comparator
Last 3 months of prior leuprolide treatment
Outcome group
Adverse events · Whole body
Studied dose
240 mg initial, then 80 or 160 mg monthly · 3 monthsAs given in this study (human).
Source sentences
Summary
With the exception of injection site reactions, the overall prevalence and pattern of AEs during the first 3 months after the switch was comparable to that during the last 3 months leuprolide treatment in the main trial.
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were 134 patients with histologically confirmed PCa who had completed 1 year of treatment with leuprolide 7.5 mg monthly before being switched to degarelix.
Summary · context
These patients were re-randomised for the extension trial to receive a starting dose of 240 mg degarelix followed by monthly maintenance doses of either 80 (n = 69) or 160 mg (n = 65).
Report a problemFND-2134237603
04HumanNon-randomized trialSafety outcome
In prostate cancer patients switching to degarelix, injection site reactions were the exception to the comparable adverse event pattern during prior leuprolide treatment.
In plain wordsIn prostate cancer patients, injection site reactions differed after switching from leuprolide to degarelix.
Peptide
Degarelix
Outcome
Direction not reportedInjection site reactions after switch
Study
n = 134
Comparator
Last 3 months of prior leuprolide treatment
Outcome group
Adverse events · Skin and wound
Studied dose
240 mg initial, then 80 or 160 mg monthly · 3 monthsAs given in this study (human).
Source sentences
Summary
With the exception of injection site reactions, the overall prevalence and pattern of AEs during the first 3 months after the switch was comparable to that during the last 3 months leuprolide treatment in the main trial.
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were 134 patients with histologically confirmed PCa who had completed 1 year of treatment with leuprolide 7.5 mg monthly before being switched to degarelix.
Summary · context
These patients were re-randomised for the extension trial to receive a starting dose of 240 mg degarelix followed by monthly maintenance doses of either 80 (n = 69) or 160 mg (n = 65).
Report a problemFND-2134237604
05HumanNon-randomized trialSafety outcome
In prostate cancer patients receiving degarelix after leuprolide, five patients (4%) discontinued due to treatment-related adverse events.
In plain wordsIn prostate cancer patients receiving degarelix after leuprolide, five patients discontinued due to treatment-related adverse events.
Peptide
Degarelix
Outcome
Not applicableTreatment-related adverse event discontinuations
Study
n = 134
Outcome group
Adverse events · Whole body
Studied dose
240 mg initial, then 80 or 160 mg monthly · 3 monthsAs given in this study (human).
Measurements
Treatment-related discontinuations
5 patients
treatment-related AEs
Treatment-related discontinuations
4%
treatment-related AEs
Source sentences
Summary
There were five (4%) patients discontinued to treatment-related AEs including injection site pain (n = 3) and fatigue (n = 2).
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were 134 patients with histologically confirmed PCa who had completed 1 year of treatment with leuprolide 7.5 mg monthly before being switched to degarelix.
Summary · context
These patients were re-randomised for the extension trial to receive a starting dose of 240 mg degarelix followed by monthly maintenance doses of either 80 (n = 69) or 160 mg (n = 65).
Report a problemFND-2134237605
06HumanNon-randomized trialSafety outcome
In prostate cancer patients receiving degarelix after leuprolide, injection site pain caused discontinuation in 3 patients.
In plain wordsIn prostate cancer patients receiving degarelix after leuprolide, injection site pain caused discontinuation in 3 patients.
Peptide
Degarelix
Outcome
Not applicableInjection site pain leading to discontinuation
Study
n = 134
Outcome group
Adverse events · Skin and wound
Studied dose
240 mg initial, then 80 or 160 mg monthly · 3 monthsAs given in this study (human).
Measurements
Injection site pain discontinuations
3 patients
degarelix
Source sentences
Summary
There were five (4%) patients discontinued to treatment-related AEs including injection site pain (n = 3) and fatigue (n = 2).
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were 134 patients with histologically confirmed PCa who had completed 1 year of treatment with leuprolide 7.5 mg monthly before being switched to degarelix.
Summary · context
These patients were re-randomised for the extension trial to receive a starting dose of 240 mg degarelix followed by monthly maintenance doses of either 80 (n = 69) or 160 mg (n = 65).
Report a problemFND-2134237606
07HumanNon-randomized trialSafety outcome
In prostate cancer patients receiving degarelix after leuprolide, fatigue caused discontinuation in 2 patients.
In plain wordsIn prostate cancer patients receiving degarelix after leuprolide, fatigue caused discontinuation in 2 patients.
Peptide
Degarelix
Outcome
Not applicableFatigue leading to discontinuation
Study
n = 134
Outcome group
Adverse events · Whole body
Studied dose
240 mg initial, then 80 or 160 mg monthly · 3 monthsAs given in this study (human).
Measurements
Fatigue discontinuations
2 patients
degarelix
Source sentences
Summary
There were five (4%) patients discontinued to treatment-related AEs including injection site pain (n = 3) and fatigue (n = 2).
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were 134 patients with histologically confirmed PCa who had completed 1 year of treatment with leuprolide 7.5 mg monthly before being switched to degarelix.
Summary · context
These patients were re-randomised for the extension trial to receive a starting dose of 240 mg degarelix followed by monthly maintenance doses of either 80 (n = 69) or 160 mg (n = 65).
Report a problemFND-2134237607

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 2
27 Oct 2026, 16:37 UTC
Study data updated · source update from Europe PMC
Version 1
27 Oct 2026, 16:34 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.